MonumenTAL-3: Talquetamab + Daratumumab Moves Earlier in Relapsed Myeloma

[Slide 1]
MonumenTAL-3: PFS (Primary Endpoint)
Tal-DP vs DPd
Tal-D vs DPd
100
24-mo PFS
100
24-mo PFS
81.3 (95% CI, 75.8-85.7)
77.6 (95% CI, 71.7-82.5)
80
Tal-DP
80
Surviving without progression, %
Median, NR
60
51.2 (95% CI, 44.8-57.1)
Surviving without progression, %
Tal-D
Median, NR
60
51.2 (95% CI, 44.8-57.1)
DPd
DPd
40
40
Median, 24.4 months
Median, 24.4 months
20
HR for progression or death:
20
HR for progression or death:
0.28 (95% CI, 0.20-0.40)
0.33 (95% CI, 0.24-0.46)
P<0.0001
P<0.0001
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
Months
No. at risk
No. at risk
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
Tal-DP
DPd
Tal-D
DPd
Tal-DP and Tal-D significantly improved PFS vs DPd
Clinical cut-off: November 3, 2025 Median follow-up of 24 6 months The O'Brien-Fleming stopping boundary for superiority was crossed for Tal-DP and Tal-D (P<0 0001 both arms; Tal-DP boundary P=0 0069; Tal-D boundary, P=0. 0145)
HR, hazard ratio
Mina R, et al N Engl J Med 2026; doi 10 1056/NEJMoa2604657 Adapted with permission © The New England Journal of Medicine (2026).
8
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026; Stockholm, Sweden

---

[Slide 2]
MonumenTAL-3: Treatment Responseᵃ and
MRD-Negative CRb Rates
OR (95% CI); all P≤0.0005
ORR: 2.27 (1.42-3.61); ECR: 4.93 (3.44-7.08)
OR (95% CI)
ORR: 2.34 (1.47-3.74); >CR: 4.40 (3.08-6.28)
10-5: 5.84 (3.94-8.64), P<0.0001; 10-6: 8.05 (5.15-12.57)
sCR
100
88.2
88.5
CR
60
10-5: 4.70 (3.16-6.98), P<0.0001; 10-6: 6.64 (4.22-10.43)
90
(253/287)
(254/287)
VGPR
77.6
PR
80
(225/290)
50
10-5
70
45.6
≥CR
24.8
60
≥CR
≥CR
34.5
ORR, %
50
71.1
>VGPR
68.9
≥VGPR
≥VGPR
9.7
MRD-negative CR rate, %
10-6
40
53.7
30
82.8
57.6
40
85.0
52.3
47.7
46.3
30
23.3
23.1
20
42.2
17.4
20
10
10
13.9
15.9
13.9
20.0
10.0
0
WE
5.6
0
Tal-DP
Tal-D
DPd
Tal-DP
Tal-D
DPd
n=287
n=287
n=290
n=287
n=287
n=290
Tal-DP and Tal-D demonstrated significantly higher ORR, ≥CR, and MRD-negative CR (10⁻⁵) rates vs DPd
Clinical cut-off: November 3, 2025. Median follow-up of 24.6 months.
"Response and disease progression were assessed by IRC per IMWG criteria. MRD negativity was assessed in bone marrow aspirates with genetic sequencing (clonoSEQ Adaptive Biotechnologies). MRD-negative CR was
defined as the absence of malignant cells at a sensitivity threshold of 10-5 or 10-6, achieved within 3 months prior to achieving CR/sCR or at any time after CR/sCR and before progression or subsequent therapy DOR, duration
of response; NR, not reached; OR, odds ratio; sCR, stringent complete response
Mina R, et al N Engl J Med 2026; doi: 10 1056/NEJMoa2604657
11
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026: Stockholm, Sweden

---

[Slide 3]
MonumenTAL-3: OS
Tal-DP vs DPd
Tal-D vs DPd
100
24-mo OS
100
24-mo OS
89.2 (95% CI, 84.9-92.4)
87.9 (95% CI, 83.0-91.5)
Tal-DP
Tal-D
80
80
DPd
DPd
79.1 (95% CI, 73.7-83.6)
79.1 (95% CI, 73.7-83.6)
60
60
Surviving, %
40
Surviving, %
40
20
20
HR for death: 0.47 (95% CI, 0.30-0.73)
HR for death: 0.51 (95% CI, 0.33-0.78)
P=0.0006
P=0.0015
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
Months
No. at risk
No. at risk
Tal-DP
287
277
276
269
262
248
238
200
141
94
48
10
0
Tal-D
287
276
275
268
264
256
251
199
130
77
40
10
0
DPd
290
278
264
255
245
226
217
173
125
78
37
4
0
DPd
290
278
264
255
245
226
217
173
125
78
37
4
0
Tal-DP and Tal-D resulted in clinically meaningful os improvement vs DPd, with >87% of patients alive
at 2 years; P-values did not cross the prespecified boundary for superiority (0.0001)
Clinical cut-off: November 3, 2025 Median follow-up of 24 6 months
Mina R, et al N Engl J Med 2026; doi 10 1056/NEJMoa2604657. Adapted with permission © The New England Journal of Medicine (2026).
12
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026; Stockholm, Sweden

---

[Slide 4]
MonumenTAL-3: Overall Safety Summary
Tal-DP
Tal-D
DPd
TEAE, n (%)
(n=276)
(n=274)
(n=283)
Any TEAE
276 (100.0)
274 (100.0)
283 (100.0)
Grade 3 or 4 TEAEs
262 (94.9)
205 (74.8)
259 (91.5)
Serious TEAEs
174 (63.0)
144 (52.6)
152 (53.7)
TEAEs leading to treatment discontinuationᵃ
29 (10.5)
22 (8.0)
19 (6.7)
TEAEs leading to death
5 (1.8)
11 (4.0)
13 (4.6)
Low rates of TEAEs leading to treatment discontinuation or death
Discontinuation of all components of study treatment
TEAE, treatment-emergent adverse event
Mina R, et al. N Engl J Med 2026; doi: 10 1056/NEJMoa2604657. Adapted with permission © The New England Journal of Medicine (2026)
13
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026; Stockholm, Sweden

Georgia McCaughan@gjmccaughan

EHA 2026 · 2026-06-13

47 impressions · 0 likes

[Slide 1]
MonumenTAL-3: Phase 3 Study Design
Primary endpoint
Key inclusion criteria
Tal-DP
(n=287)
PFS by IRC
Age >18 years
Measurable RRMM
Key secondary endpoints
ORRª
≥1 prior LOT including Len and a PI
1:1:1
Tal-D
ECOG PS 0-2
randomization
≥CRᵃ
(n=287)
N=864
MRD-negative CR
Key exclusion criteria
Refractory to anti-CD38 mAb
4 Nov 2022 to
OS
13 Mar 2025
DPd
Additional secondary endpoints
Prior GPRC5D, Pom, or T-cell redirecting
therapy within 3 months before randomization
(n=290)
Safety
Tal Q4W permitted
Tal Q4W required
with 2VGPR at
with 2PR at cycle 7
cycle 5-6
and beyond
Regimen
C1-2
C3-4
C5-6
C7+
Tal: 0.8 mg/kg
Tal was given SC
Tal-DP
Q2W
Q2W
Q2W
Q2W
Dara: 1800 mg
with step-up dosing
QW
Q2W
Q2W
Q4W
Pom:
at 0.01, 0.06, and
- Tal-DP: 2 mg daily
0.4 mg/kg, followed
(D1-21)
by 0.8 mg/kg
Tal-Dᵇ
Q2W
Q2W
Q2W
Q2W
- DPd: 4 mg daily
QW
Q2W
Q2W
Q4W
(D1-21)
ClinicalTrials gov identifier: NCT05455320. "Response and disease progression were assessed by 8 blinded IRC por IMWG criteria. Dexamethasone, acetaminophen, and diphenhydramine premedication was required for the
first 2 weeks; subsequent dexamethasone was not required thereafter. Pom is given from cycle 2 *Pom dose could be increased to 4 mg at the start of cycle 3 day 1 or after per the investigator's discretion C, cycle; CR,
complete response; D, day; ECOG PS, Eastem Cooperative Oncology Group performance status; IMWG, International Myeloma Working Group; IRC, independent review committee; Len, lonalidomide, MRD, measurabie
residual disease; ORR, overall response rate; OS, overall survival; PR, partial response Q2W, every 2 weeks; Q4W, every 4 weeks; QW, weekly; SC, subculaneously, VGPR, very good partial response.
Mina R, et al. N Engl J Med 2026; doi: 0.1056/NEJMoa2604657.
4
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress June 11-14, 2026; Stockholm, Sweden

---

[Slide 2]
MonumenTAL-3: PFS (Primary Endpoint)
Tal-DP VS DPd
Tal-D VS DPd
100
24-mo PFS
100
24-mo PFS
81.3 (95% CI, 75.8-85.7)
80
Tal-DP
77.6 (95% CI, 71.7-82.5)
80
Surviving without progression, %
Median, NR
51.2 (95% CI, 44.8-57.1)
Surviving without progression, %
Tal-D
Median, NR
60
60
51.2 (95% CI, 44.8-57.1)
DPd
DPd
40
Median, 24.4 months
40
Median, 24.4 months
20
HR for progression or death:
20
HR for progression or death:
0.28 (95% CI, 0.20-0.40)
0.33 (95% CI, 0.24-0.46)
P<0.0001
P<0.0001
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at risk
Months
No. at risk
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
Tal-DP
DPd
Tal-D
DPd
Tal-DP and Tal-D significantly improved PFS vs DPd
Clinical cut-off: November 3, 2025. Median follow-up of 24.6 months. The O'Brien-Fleming stopping boundary for superiority was crossed for Tal-DP and Tal-D (P<0.0001 both arms; Tal DP boundary, P=0 0069; Tal-D boundary, P=0 0145).
HR, hazard ratio.
Mina R, et al. N Engl J Med 2026; doi: 0.1056/NEJMoa2604657. Adapted with permission © The New England Journal of Medicine (2026).
B
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026; Stockholes, Sweden

---

[Slide 3]
Monumer TAL-3: Most Commona AEs¹
Higher rate of
Tal-DP
Tal-D
DPd
TEAE, n (%)
(n=278)
(n=274)
neutropenia with Tal-DP
(п=283)
Any Grade
Grade 3/4
and DPd VS Tal-D,
Any Grade
Grade 3/4
Any Grade
Grado 3/4
Neutropenia
232 (84.1)
consistent with known
211 (76.4)
112 (40.9)
80 (29.2)
255 (90.1)
244 (86.2)
Anemia
Hematologic
136 (49.3)
66 (23.9)
profile of Pom²-³
107 (39.1)
41 (15.0)
117 (41.3)
45 (15.9)
Thrombocytopenia
136 (49.3)
66 (23.9)
93 (33.9)
36 (13.1)
108 (38.2)
39 (13.8)
With Tal-DP and Tal-D,
Lymphopenia
99 (35.9)
86 (31.2)
82 (29.9)
68 (24.8)
72 (25.4)
50 (17.7)
CRS mostly grade 1
Infections
241 (87,3)
104 (37.7)
231 (84.3)
80 (29.2)
235 (83.0)
120 (42.2)
(55.8%, 48.9%), with
Taste changesᵇ
201 (72.8)
IN
205 (74.8)
I
11 (3.9)
-
11.2% and 8.8% grade 2
Non-rash skin AE
191 (69.2)
6 (2.2)
177 (64.6)
7 (2.6)
24 (8.5)
0
CRS
187 (67.8)
2 (0.7)
160 (58.4)
2 (0.7)
E
$
- All but 1 event
Non-
Nail-related AEd
hematologic
155 (56.2)
1 (0.4)
157 (57.3)
1 (0.4)
1 (0.4)
0
resolved
Pyrexia
127 (46.0)
8 (2.9)
112 (40.9)
3 (1.1)
35 (12.4)
2 (0.7)
ICANS: 2.9% (Tal-DP),
Decreased weight
126 (45.7)
21 (7.6)
105 (38.3)
13 (4.7)
21 (7.4)
1 (0.4)
1.8% (Tal-D); all resolved
Rash AE°
105 (38.0)
5 (1.8)
107 (39.1)
7 (2.6)
43 (15.2)
1 (0.4)
Fatigue
83 (30.1)
14 (5.1)
60 (21.9)
8 (2.9)
69 (24.4)
9 (3.2)
The safety profiles of Tal-DP and Tal-D were consistent with known effects of each agent
*>30% of patients in any treatment am *Tasto changes included dysgeusia, ageusia, hypogeusia, and lasta disorder Per the Common Terminology Critoria for Adverse Events, the maximum severity for taste changes is grade 9
Non-rash skin adverse events included skin exfoliation, dry skin, palmar plantar erythiodysesthesia and pruntus Nail related adverse events included nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis,
and nail ridging *Rash adverse events included rash, maculopapular rash, erythematous rash, and erythema AE, adverse event CRS, cytokine release syndrome, ICANS, inmuno ellector coll-associated neuroloxicily syndrome
1. Mina R, et al N Engl J Med 2026; doi: 10 1056/NEJMoa2604657. Adapted with permission D The New England Journal of Medicina (2026) 2. Denopoutos MA of al Lancel Oncel 2021.22 601-12 3 Richardson PG, at al
Lancel Oncol 2019,20 781-04
14
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress, June 11-14. 2026, Stockholm, Sweden

---

[Slide 4]
Monumen TAL-3: AEs of Interest
Tal-DP
Tal-D
DPd
Tal-DP
Tal-D
DPd
AE, n (%)
AE, n (%)
(n=276)
(n=274)
(n=283)
(n=276)
(n=274)
(n=283)
Taste changesᵃ
201 (72.8)
205 (74.8)
11 (3.9)
Weight decreased
126 (45.7)
105 (38.3)
21 (7.4)
Grade 3 or 4
-
-
-
Grade 3ᵈ
21 (7.6)
13 (4.7)
1 (0.4)
Leading to
Leading to
11 (4.0)
6 (2.2)
-
6 (2.2)
5 (1.8)
-
discontinuation of Tal
discontinuation of Tal
Events resolvedb
131 (58.0)
129 (56.3)
4 (36.4)
Events resolvedᵇ
111 (68.5)
115 (79.9)
22 (78.6)
Non-rash skinc
191 (69.2)
177 (64.6)
24 (8.5)
Rash-related
105 (38.0)
107 (39.1)
43 (15.2)
Grade 3d
6 (2.2)
7 (2.6)
0
Grade 3d
5 (1.8)
7 (2.6)
1 (0.4)
Leading to
Leading to
5 (1.8)
2 (0.7)
-
1 (0.4)
2 (0.7)
-
discontinuation of Tal
discontinuation of Tal
Events resolvedb
279 (80.2)
215 (73.9)
21 (80,8)
Events resolvedᵇ
161 (93.1)
129 (84.9)
51 (91.1)
Nail related
155 (56.2)
157 (57.3)
1 (0.4)
Ataxia/balance disorders9
40 (14.5)
34 (12.4)
1 (0.4)
Grade 3d
1 (0.4)
1 (0.4)
0
Grade 3d
8 (2.9)
6 (2.2)
0
Leading to
Leading to
3 (1.1)
0
-
discontinuation of Tal
13 (4.7)
6 (2.2)
-
discontinuation of Tal
Events resolvedb
109 (54.8)
90 (43.7)
1 (100.0)
Events resolvedᵇ
10 (10.8)
11 (16.9)
0
AEs of interest were predominantly low grade and infrequently led to Tal discontinuation
Taste changes included dysgeusia, ageusia, hypogeusia, and taste disorder. Per the Common Terminology Critena for Adverse Events, the maximum severity for taste changes is grade 2. Parcent of events resolved is
calculated using the total number of events for the respective AE as the denominator. Non-rash skin adverse events included skin exfoliation, dry skin, palmar plantar erythrodysesthesia and pruntus. There were no grade 24
events Nail-related adverse events included nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, and nail ridging. Rash adverse events included cash, maculopapular rash, erythematous rash, and
erythema. Ataxia/balance disorders included ataxia, dysarthria, balance disorder, nystagmus, cerebellar ataxia, cerebellar syndrome, dysmetria, and gait disturbance
Mina R, et al. N Engl J Med 2026; doi: 0.1056/NEJMoa2604657. Adapted with permission D The New England Journal of Medicine (2026).
16
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress June 11-14, 2020, Stockholm, Sweden

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

416 impressions · 5 likes

[Slide 1]
Figure S2. Patient Disposition
1104 Patients were
screened for eligibility
240 Patients failed screening
237 did not meet eligibility criteria
3 withdrew consent
864 Patients were
randomized (intent-to-treat
analysis set)
287 Assigned to
Tal-DP
287 Assigned
290 Assigned
to Tal-D
to DPd
11 Patients
13 Patients
7 Patients did
did not
did not
not receive
receive study
receive study
study
treatment
treatment
treatment
276 Received
274 Received
283 Received
37 Discontinued study
Tal-DP
41 Discontinued study
Tal-D
DPd treatment
67 Discontinued study
participation
treatment
participation
treatment
(safety
participation
30 due to death
(safety
34 due to death
(safety
analysis set)
59 due to death
1 lost to follow-up
analysis set)
1 lost to follow-up
analysis set)
8 patient withdrawal
6 patient withdrawal
6 patient withdrawal
82 Discontinued study
83 Discontinued study
149 Discontinued study
treatment
treatment
treatment
35 due to adverse event
23 due to adverse event
20 due to adverse event
1 lost to follow-up
5 due to physician decision
11 due to physician decision
4 due to physician decision
43 due to progressive disease
114 due to progressive disease
37 due to progressive disease
11 patients refused further
3 patients refused further
5 patients refused further
treatment
treatment
treatment
194 Patients still
1 other
191 Patients still
134 Patients still
1 other
on treatment
on treatment
on treatment
Eligible patients were randomized to receive talquetamab in combination with daratumumab and pomalidomide (Tal-DP), talquetamab in combination with
daratumumab (Tal-D), or daratumumab in combination with pomalidomide and dexamethasone (DPd).

---

[Slide 2]
Table S6. Relative Dose Intensity (Safety Population)*
Tal-DP
Tal-D
DPd
(N=276)
(N=274)
(N=283)
Talquetamab relative dose intensity, .:
No.
275
273
-
Median, % (range)
95.4 (5-109)
97.1 (6-108)
-
Daratumumab relative dose intensity
No.
276
274
283
Median, % (range)
96.9 (33-109)
100 (33-150)
94.6 (6-100)
Pomalidomide relative dose intensity
No.
270
-
283
Median, % (range)
82.0 (5-104)
-
75.6 (9-100)
Tal-DP, talquetamab plus daratumumab and pomalidomide Tal-D, talquetamab plus daratumumab; DPd, daratumumab plus
pomalidomide and dexamethasone.
* Safety population includes all patients who received at least one dose of study treatment.
+ Includes step-up doses and any repeated step-up doses, if applicable. For talquetamab, patients who switched to the
monthly schedule received a planned dose of 0.8 mg/kg every 4 weeks. Switching at Cycle 5 was optional for patients who
achieved very good partial response or better at investigator discretion. From Cycle 7, switching to 0.8 mg/kg every 4 weeks
was required for patients who achieved partial response or better.
# Relative dose intensity is calculated considering planned dose per protocol.

---

[Slide 3]
Table S7. Treatment Cycle Delays, Incidence, and Reasons for Study Treatment Dose
Modification (Safety Population)*
Tal-DP
Tal-D
DPd
(N=276)
(N=274)
(N=283)
Patients with >1 cycle delays, n (%)
226 (81.9)
201 (73.4)
155 (54.8)
Patients who received talquetamab, n (%) t.t
275 (99.6)
273 (99.6)
-
Patients with talquetamab skipped, n (%)§
174 (63.3)
120 (44.0)
-
Patients with talquetamab delay, n (%)$
58 (21.1)
59 (21.6)
-
Patients who received daratumumab, n (%)+
276 (100)
274 (100)
283 (100)
Patients with daratumumab skipped, n (%)$
196 (71.0)
143 (52.2)
214 (75.6)
Patients with daratumumab delay, n (%)$
63 (22.8)
55 (20.1)
15 (5.3)
Patients who received pomalidomide, n (%)+
270 (97.8)
-
283 (100)
Patients with pomalidomide skipped, n (%)$
222 (82.2)
-
231 (81.6)
Patients with pomalidomide reduced, n (%)$
114 (42.2)
-
171 (60.4)
Tal-DP, talquetamab plus daratumumab and pomalidomide Tal-D, talquetamab plus daratumumab; DPd, daratumumab plus
pomalidomide and dexamethasone.
* Safety population includes all patients who received at least one dose of study treatment.
+ Percentages are calculated with the number of patients in the safety population in each treatment arm as the denominator.
$ Includes patients who received at least one dose of talquetamab.
$ Percentages are calculated with the number of patients who received the corresponding drug as the denominator.

Breno Moreno de Gusmo@morenodegusmao

EHA 2026 · 2026-06-13

71 impressions · 1 likes

[Slide 1]
MonumenTAL-3: PFS (Primary Endpoint)
Tal-DP vs DPd
Tal-D vs DPd
100
24-mo PFS
100
24-mo PFS
81.3 (95% CI, 75.8-85.7)
80
Tal-DP
80
77.6 (95% CI, 71.7-82.5)
Surviving without progression, %
Median, NR
51.2 (95% CI, 44.8-57.1)
Surviving without progression, %
Tal-D
60
Median, NR
60
51.2 (95% CI, 44.8-57.1)
DPd
40
DPd
Median, 24.4 months
40
Median, 24.4 months
20
HR for progression or death:
20
HR for progression or death:
0.28 (95% CI, 0.20-0.40)
0.33 (95% CI, 0.24-0.46)
P<0.0001
P<0.0001
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at risk
Months
No. at risk
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
Tal-DP
DPd
Tal-D
DPd
Tal-DP and Tal-D significantly improved PFS vs DPd
Clinical cut off November 3, 2025 Median follow up of 24.6 months The Brien Fleming stopping boundary for superiority was crossed for Tal OP and Tal-D (Pro 0001 both arms, Tal OP boundary, Pio 0069; Tal 0 boundary, Pr0.0145)
HR, hazard rabo,
Mina R, ot at N Engl J Med 2026; doc 10 1056/NEJMoa2604657. Adapted with permission 0 The New England Journal of Medicine (2026)
$
Presented by P Voorhoes at the European Hematology Association (EHA) 2026 Congress, June 11-14,2026 Stockholm, Swedon

---

[Slide 2]
Monumen TAL-3: Treatment Responseᵃ and
MRD-Negative CRb Rates
OR (95% CI); all P$0.0005
ORR: 2.27 (1.42-3.61); 2CR: 4.93 (3.44-7.08)
OR (95% CI)
ORR: 2.34 (1.47-3.74): 2CR: 4.40 (3.08-6.28)
10 ⁵: 5.84 (3.94-8.64), P<0.0001; 10 4: 8.05 (5.15-12.57)
sCR
100
88.2
88.5
CR
60
10-3: 4.70 (3.16-8.98). P<0.0001; 10 4: 6.64 (4.22-10.43)
90
(253/287)
(254/287)
VGPR
77.6
PR
80
(225/290)
50
10⁵
70
45.6
>CR
24.8
60
ORR, %
2CR
>CR
34.5
50
71.1
2VGPR
68.9
2VGPR
2VGPR
9.7
MRD-negative CR rate, %
40
10
53.7
30
85.0
82.8
57.6
40
52.3
47.7
46.3
30
23.3
23.1
20
42.2
17.4
20
10
10
13.9
13.9
20.0
15.9
10.0
5.6
0
0
Tal-DP
Tal-D
DPd
Tal-DP
Tal-D
DPd
n=287
n=287
n=290
n=287
n=287
n=290
Tal-DP and Tal-D demonstrated significantly higher ORR, >CR, and MRD-negative CR (10-5) rates vs DPd
Clinical cut off: November 3, 2025 Median follow up of 24.6 months
Response and disease progression were assessed by IRC por IMWG criteria MRD negativity was assessed in bone marrow aspirates with genetic sequencing (clonoSEQ Adaptive Biolechnologies). MRD. negative CR was
defined as the absence of malignant cells at a sensitivity threshold of 10-For 10*, achieved within 3 months prior to achieving CR/sCR or at any time after CR/sCR and before progression or subsequent therapy DOR, duration
of response; NR, not reached OR, odds ratio, sCR, stringent complete response
Mina R, of at N Engl J Med 2026; doc 10 1056/NEJMoa2604657
11
Presented by P Voorhees at the European Homatology Association (EHA) 2026 Congress June 11-14, 2026, Stockholm, Sweden

---

[Slide 3]
MonumenTAL-3: AEs of Interest
Tal-DP
AE, n (%)
Tal-D
DPd
Tal-DP
AE, n (%)
Tal-D
DPd
(n=276)
(n=274)
(n=283)
(n=276)
(n=274)
(n=283)
Taste changes
201 (72.8)
205 (74.8)
11 (3.9)
Weight decreased
126 (45.7)
105 (38.3)
21 (7.4)
Grade 3 or 4
-
-
-
Grade 3d
21 (7.6)
13 (4.7)
1 (0.4)
Leading to
11 (4.0)
6 (2.2)
Leading to
-
discontinuation of Tal
discontinuation of Tal
6 (2.2)
5 (1.8)
-
Events resolvedb
131 (58.0)
129 (56.3)
4 (36.4)
Events resolved
111 (68.5)
115 (79.9)
22 (78.6)
Non-rash skinc
191 (69.2)
177 (64.6)
24 (8.5)
Rash-related
105 (38.0)
107 (39.1)
43 (15.2)
Grade 3d
6 (2.2)
7 (2.6)
0
Grade 3d
5 (1.8)
7 (2.6)
1 (0.4)
Leading to
5 (1.8)
2 (0.7)
Leading to
-
discontinuation of Tal
discontinuation of Tal
1 (0.4)
2 (0.7)
-
Events resolvedᵇ
279 (80.2)
215 (73.9)
21 (80.8)
Events resolved
161 (93.1)
129 (84.9)
51 (91.1)
Nail related
155 (56.2)
157 (57.3)
1 (0.4)
Ataxia/balance disorders9
40 (14.5)
34 (12.4)
1 (0.4)
Grade 3d
1 (0.4)
1 (0.4)
0
Grade 3d
8 (2.9)
6 (2.2)
0
Leading to
Leading to
3 (1.1)
0
-
discontinuation of Tal
13 (4.7)
discontinuation of Tal
6 (2.2)
-
Events resolved
109 (54.8)
90 (43.7)
1 (100.0)
Events resolvedb
10 (10.8)
11 (16.9)
0
AEs of interest were predominantly low grade and infrequently led to Tal discontinuation
*Taste changes included dysgeusia, ageusia, hypogeusia, and taste disorder Per the Common Terminology Criteria for Adverse Events, the maximum severity for taste changes is grade 2. Percent of events resolved is
calculated using the total number of events for the respective AE as the denominator Non rash skin adverse events included skin exfoliation, dry skn palmar plantar erythrodyses/hesia and pruntus. There were no grade 14
events "Nail related adverse events included nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, and nail ridging "Rash adverse events included rash, maculopapular rash, erythematous rash, and
erythema. Ataxia/balance disorders included staxis dysarthia, balance disorder, nystagmus, cerebellar staxis, cerebellar syndrome, dysmetria, and part disturbance
Mina R, of al. N Engl J Med 2026; doc 10 dapted with permission © The New England Journal of Medicine (2026)
16
Voorhees at the European Hematology Association (EHA) 2026 Congress, June 11-14,2026 Stockholm, Sweden

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

391 impressions · 4 likes

[Slide 1]
A Progression-free Survival, Tal-DP vs. DPd
24-mo Progression-free
survival
100
90
Tal-DP
80
81.3 (95% CI,
Percentage of Patients Alive
without Disease Progression
70
75.8-85.7)
60
50
DPd
40
51.2 (95% CI,
44.8-57.1)
30
20
Hazard ratio for disease progression
10
or death, 0.28 (95% CI, 0.20-0.40)
P<0.001
0
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at Risk
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
B Progression-free Survival, Tal-D vs. DPd
24-mo Progression-free
survival
100
90
77.6 (95% CI,
71.7-82.5)
80
Tal-D
Percentage of Patients Alive
without Disease Progression
70
60
50
DPd
40
51.2 (95% CI,
44.8-57.1)
30
20
Hazard ratio for disease progression
10
or death, 0.33 (95% CI, 0.24-0.46)
P<0.001
0
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at Risk
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
Figure 1. Progression-free Survival (Intention-to-Treat Population).
Shown are Kaplan-Meier estimates of progression-free survival in the
Tal-DP group as compared with the DPd group (Panel A) and in the Tal-D
group as compared with the DPd group (Panel B). Tick marks indicate cen-
sored data. At a median follow-up of 24.6 months, the P values for Tal-DP
and Tal-D crossed the O'Brien-Fleming stopping boundaries for superiority
(P=0.0069 for Tal-DP; P=0.0145 for Tal-D). Median progression-free sur-
vival could not be estimated in the Tal-DP and Tal-D groups and was 24.4
months (95% CI, 19.3 to not estimated) in the DPd group. At the clinical
cutoff, disease progression or death had occurred in 241 of 864 patients:
48 in the Tal-DP group, 57 in the Tal-D group, and 136 in the DPd group.
The intention-to-treat population included all the patients who had under-
gone randomization. DPd denotes daratumumab plus pomalidomide and
dexamethasone, Tal-D talquetamab plus daratumumab, and Tal-DP talque-
tamab plus daratumumab and pomalidomide.

---

[Slide 2]
A Overall Survival, Tal-DP vs. DPd
24-mo Overall
survival
100
89.2 (95% CI,
84.9-92.4)
Tal-DP
90
80
70
79.1 (95% CI,
DPd
Percentage of Patients Alive
73.7-83.6)
60
50
40
30
20
10
Hazard ratio for death, 0.47
(95% CI, 0.30-0.73)
0
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at Risk
Tal-DP
287
277
276
269
262
248
238
200
141
94
48
10
0
DPd
290
278
264
255
245
226
217
173
125
78
37
4
0
B Overall Survival, Tal-D vs. DPd
24-mo Overall
survival
100
87.9 (95% CI,
83.0-91.5)
90
Tal-D
80
70
79.1 (95% CI,
DPd
Percentage of Patients Alive
73.7-83.6)
60
50
40
30
20
10
Hazard ratio for death, 0.51
(95% CI, 0.33-0.78)
0
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
No. at Risk
Tal-D
287
276
275
268
264
256
251
199
130
77
40
10
0
DPd
290
278
264
255
245
226
217
173
125
78
37
4
0
Figure 2. Overall Survival (Intention-to-Treat Population).
Shown are Kaplan-Meier estimates of overall survival in the Tal-DP group
as compared with the DPd group (Panel A) and in the Tal-D group as com-
pared with the DPd group (Panel B). Tick marks indicate censored data. At
a median follow-up of 24.6 months, the P values (P=0.0006 for Tal-DP;
P=0.0015 for Tal-D) did not cross the prespecified stopping boundaries for
superiority, given the nominal alpha level allocated for each comparison at
the interim analysis (0.0001). At the clinical cutoff, death had occurred in
123 of 864 patients: 30 in the Tal-DP group, 34 in the Tal-D group, and 59
in the DPd group. The intention-to-treat population included all the pa-
tients who had undergone randomization.

Rahul Banerjee, MD, FACP@rahulbanerjeemd

EHA 2026 · 2026-06-13

378 impressions · 12 likes

[Slide 1]
Monumen TAL-3: PFS (Primary Endpoint)
Tal-DP vs DPd
Tal-D vs DPd
100
24-mo PFS
100
24-mo PFS
81.3 (95% CI, 75.8-85.7)
77.6 (95% CI, 71.7-82.5)
80
Tal-DP
80
Surviving without progression, %
Median, NR
60
51.2 (95% CI, 44.8-57.1)
Surviving without progression, %
Tal-D
Median, NR
60
51.2 (95% CI, 44.8-57.1)
DPd
DPd
40
40
Median, 24.4 months
Median, 24.4 months
20
HR for progression or death:
20
HR for progression or death:
0.28 (95% CI, 0.20-0.40)
0.33 (95% CI, 0.24-0.46)
P<0.0001
P<0.0001
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
Months
No. at risk
No. at risk
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
Tal-DP
DPd
Tal-D
DPd
Tal-DP and Tal-D significantly improved PFS vs DPd
Clinical cut off: November 3, 2025 Median follow up of 24 6 months The O'Brien-Fleming stopping boundary for superiority was crossed for Tal DP and Tal-D (P<0 0001 both arms, Tal DP boundary, P=0 0069, Tal 0 boundary, P=0.0145)
HR, hazard ratio
Mina R, of al N Engl J Med 10 056/NE.IMoa2604657. Adapted with permission o The New England Journal of Medicine (2026)
8
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress; June 11-14, 2026, Stockholm, Sweden

---

[Slide 2]
MonumenTAL-3: OS
Tal-DP vs DPd
Tal-D vs DPd
100
24-mo OS
100
24-mo OS
89.2 (95% CI, 84.9-92.4)
87.9 (95% CI, 83.0-91.5)
Tal-DP
Tal-D
80
80
DPd
DPd
79.1 (95% CI, 73.7-83.6)
79.1 (95% CI, 73.7-83.6)
60
60
Surviving, %
40
Surviving, %
40
20
20
HR for death: 0.47 (95% CI, 0.30-0.73)
HR for death: 0.51 (95% CI, 0.33-0.78)
P=0.0006
P=0.0015
0
0
0
3
6
9
12
15
18
21
24
27
30
33
36
0
3
6
9
12
15
18
21
24
27
30
33
36
Months
Months
No. at risk
No. at risk
Tal-DP
287
277
276
269
262
248
238
200
141
94
48
10
0
Tal-D
287
276
275
268
264
256
251
199
130
77
40
10
0
DPd 290 278 264 255 245 226 217 173 125 78 37 4
0
DPd 290 278 264 255 245 226 217 173 125 78 37 4
0
Tal-DP and Tal-D resulted in clinically meaningful os improvement vs DPd, with >87% of patients alive
at 2 years; P-values did not cross the prespecified boundary for superiority (0.0001)
Clinical cut-off November 3, 2025. Median follow-up of 24.6 months
Mina R, et al N Engl J Med 2026; doi: 10. 1056/NEJMoa2604657 Adapted with permission © The New England Journal of Medicine (2026)
12
Presented by P Voorhees at the European Hematology Association (EHA) 2026 Congress, June 11-14, 2026; Stockholm, Sweden

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

180 impressions · 2 likes

[Slide 1]
Table S20. GPRC5D-associated Adverse Events (Safety Population)*
Tal-DP
Tal-D
DPd
Parameter
(N=276)
(N=274)
(N=283)
Taste changes +
201 (72.8)
205 (74.8)
11(3.9)
Leading to talquetamab dose delays or skips, n (%)
18 (6.5)
15 (5.5)
Leading to discontinuation of talquetamab, n (%);
11 (4.0)
6(2.2)
-
Leading to discontinuation of all study treatment, n (%)
5(1.8)
0
0
Duration, median (range). days
183 (3-909)
217 (2-934)
169(1-353)
Patients who received supportive measures, n (%)
8(13.8)
(10.9)
0
Outcome, (%)'
Number of events
226
229
11
Recovered or resolved
(58.0)
129 (56.3)
4(36.4)
Not recovered or resolved
86 (38.1)
(40.2)
7(63.6)
Recovered or resolved with sequelae
1 (0.4)
1 (0.4)
0
Recovering or resolving
1 (0.4)
2(0.9)
0
Missing
7(3.1)
5(2.2)
0
Non-rash skin adverse events #
191 (69.2)
177 (64.6)
24(8.5)
Grade 3.n (%) **
6(2.2)
7(2.6)
0
Leading to talquetamab dose delays or skips, n (%)
12 (4.3)
10 (3.6)
-
Leading to discontinuation of talquetamab, n (%):
5(1.8)
2(0.7)
-
Leading to discontinuation of all study treatment, n (%)$
2(0.7)
1 (0.4)
0
Duration, median (range). days
43
46
13
(1-714)
(1-732)
(2-512)
Patients who received supportive measures, n (%)
113(40.9)
107 (39.1)
13(4.6)
Outcome. (%)
Number of events
348
291
26
Recovered or resolved
279(80.2)
(73.9)
21 (80.8)
Not recovered or resolved
63(18.1)
71(24.4)
5(19.2)
Recovered or resolve with sequelae
1 (0.3)
1 (0.3)
0
Recovering or resolving
1 (0.3)
1 (0.3)
0
Missing
4(1.1)
3(1.0)
0
Nail-related adverse events
155(56.2)
57(57.3)
1 (0.4)
Grade (%) **
1 (0.4)
1 (0.4)
0
Leading to talquetamab dose delays or skips, n (%)
4(1.4)
4(1.5)
Leading to discontinuation of talquetamab, n (%):
3(1.1)
0
0
Leading to discontinuation of all study treatment. n (%)3
0
0
0
Duration, median (range). days
176(1-815)
171 (1-924)
(64-64)
Patients who received supportive measures, n (%)
(12.7)
30(10.9)
0
Outcome, (%)
Number of events
199
206
1
Recovered or resolved
109 (54.8)
90(43.7)
1 (100)
Not recovered or resolved
83(41.7)
(49.0)
0
Recovered or resolve with sequelae
0
0
0
Recovering or resolving
3(1.5)
2(1.0)
0
Missing
4(2.0)
13 (6.3)
0
Rash-related adverse events **
105 (38.0)
107 (39.1)
43(15.2)
Grade (%) **
5(1.8)
7(2.6)
1 (0.4)
Leading to talquetamab dose delays or skips, n (%)
7(2.5)
5(1.8)
Leading to discontinuation of talquetamab, n (%):
1 (0.4)
2(0.7)
Leading to discontinuation of all study treatment, n (%) $
0
1 (0.4)
0
Duration, median (range). days
21 (1-920)
(1-662)
9(1-121)
Patients who received supportive measures, n (%)
75 (27.2)
84(30.7)
32(11.3)
Outcome, n (%)
43
Tal-DP
Tal-D
DPd
Parameter
(N=276)
(N=274)
(N=283)
Number of events
173
152
56
Recovered or resolved
161 (93.1)
129 (84.9)
51 (91.1)
Not recovered or resolved
11(6.4)
(13.8)
4(7.1)
Recovered or resolve with sequelae
0
1 (0.7)
0
Recovering or resolving
0
1 (0.7)
0
Missing
1 (0.6)
0
1 (1.8)
Tal-DP. talquetamab plus daratumumab and pomalidomide; Tal-D, talquetamab plus daratumumab; DPd, daratumumab
plus pomalidomide and dexamethasone
*The fety population was defined as all randomized patients who received at least one dose of study treatment
f Including ageusia, dysgeusia (maximum grade 2 severity per Common Terminology Criteria for Adverse Events v5.0),
hypogeusia, and taste disorder.
: Events with action taken to talquetamab as drug withdraws on the adverse event electronic clinical report form page.
$ Includes those patients indicated as having discontinued all study treatment due to adverse events on the I-of-treatment
clinical report form page.
Total number of events for the given treatment arm is used as the denominator.
# Including skin exfoliation, dry skin, pruntus, and palmar-plantar erythrodysesthesia syndrome.
I Including nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, nail dystrophy, nail toxicity, and
nail ridging.
Including rash, maculopapular rash, crythematous rash, and erythema.
ff There were no grade N events.

---

[Slide 2]
Figure S5. Mean Body Mass Index (kg/m²) Over Time by Body Mass Index at Baseline (Safety Population)
(A) Tal-DP
40
Obese
Mean (SE) Body Mass Index (kg/m²)
D.
X
30
@
D
Overweight
Healthy weight
20
0
Underweight
C201
C3D1
CAD1
CSD1
C6D1
CTD1
CBD1
C9D1
C1001
C1C101201
C1301
C1401
C1501
C1601
C1701
C1801
C1901
C2002101
10223
C23D1
C24D1
C25D1
C2801
C3001
C34D1
Visit
No. of Patients
Underweight 3 3 3 3 3 3 3 3 3 3 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
Healthy weight
94
90
89
85
80
80
78
74
73
68
64
61
61
58
55
54
51
49
48
46
44
43
38
36
31
27
26
20
14
12
9
7
6
5
4
3
1
0
0
Overweight
117
110
105
104
102
97
96
95
89
89
88
84
84
83
80
77
76
74
72
72
69
63
55
43
32
30
27
26
21
21
17
10
9
6
5
2
1
1
1
Obese 62 59 57 56 53 53 54 53 51 52 50 51 48 48 47 47 46 46 47 42 39 38 35 28 26 26 22 17 12 10 8 5 3 2 1 1 1 1 0
Underweight
Healthy weight
Overweight
-
-
Obese

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

138 impressions · 2 likes

[Slide 1]
Table 3. Most Common Adverse Events (Safety Population).*
Tal-DP
Tal-D
DPd
Event
=276)
N=274)
(N=283)
Any Grade
Grade 3 or 4
Any Grade
Grade 3 or 4
Any Grade
Grade 3 or 4
number of patients (percent)
Any adverse event
276 (100.0)
267 (96.7)
274 (100.0)
216 (78.8)
283 (100.0)
271 (95.8)
Hematologic
Neutropenia
232 (84.1)
211 (76.4)
112 (40.9)
80 (29.2)
255 (90.1)
244 (86.2)
Anemia
136 (49.3)
66 (23.9)
107 (39.1)
41 (15.0)
117 (41.3)
45 (15.9)
Thrombocytopenia
136 (49.3)
66 (23.9)
93 (33.9)
36 (13.1)
108 (38.2)
39 (13.8)
Lymphopenia
99 (35.9)
86 (31.2)
82 (29.9)
68 (24.8)
72 (25.4)
50 (17.7)
Leukopenia
94 (34.1)
63 (22.8)
53 (19.3)
26 (9.5)
79 (27.9)
60 (21.2)
Nonhematologic
Infection
241 (87.3)
104 (37.7)
231 (84.3)
80 (29.2)
235 (83.0)
120 (42.4)
Taste change+
201 (72.8)
—
205 (74.8)
—
11 (3.9)
-
Nonrash skin adverse event
191 (69.2)
6 (2.2)
177 (64.6)
7 (2.6)
24 (8.5)
0
Cytokine release syndrome
187 (67.8)
2 (0.7)
160 (58.4)
2 (0.7)
-
-
Nail-related adverse eventS
155 (56.2)
1 (0.4)
157 (57.3)
1 (0.4)
1 (0.4)
0
Pyrexia
127 (46.0)
8 (2.9)
112 (40.9)
3 (1.1)
35 (12.4)
2 (0.7)
Decreased weight
126 (45.7)
21 (7.6)
105 (38.3)
13 (4.7)
21 (7.4)
1 (0.4)
Rash-related adverse event
105 (38.0)
5 (1.8)
107 (39.1)
7 (2.6)
43 (15.2)
1 (0.4)
Diarrhea
104 (37.7)
7 (2.5)
81 (29.6)
2 (0.7)
79 (27.9)
13 (4.6)
Fatigue
83 (30.1)
14 (5.1)
60 (21.9)
8 (2.9)
69 (24.4)
9 (3.2)
Nausea
79 (28.6)
1 (0.4)
50 (18.2)
1 (0.4)
34 (12.0)
1 (0.4)
Dry mouth
77 (27.9)
1 (0.4)
73 (26.6)
0
3 (1.1)
0
Cough
74 (26.8)
2 (0.7)
70 (25.5)
0
50 (17.7)
1 (0.4)
Hypokalemia
68 (24.6)
17 (6.2)
55 (20.1)
10 (3.6)
45 (15.9)
9 (3.2)
* Shown are adverse events of any grade that occurred in at least 20% of the patients in any trial group. Adverse events were graded with the
Common Terminology Criteria for Adverse Events, version 5.0. The safety population included all the patients who had received at least one
dose of the trial treatment. Safety analyses were conducted according to the treatment received.
f Taste changes included dysgeusia, ageusia, hypogeusia, and taste disorder. According to the Common Terminology Criteria for Adverse
Events, the maximum severity for dysgeusia is grade 2.
$ Nonrash skin adverse events included skin exfoliation, dry skin, pruritus, and palmar-plantar erythrodysesthesia syndrome.
I Nail-related adverse events included nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, and nail ridging.
Rash-related adverse events included rash, maculopapular rash, erythematous rash, and erythema.

---

[Slide 2]
Table 3. Most Common Adverse Events (Safety Population).*
Tal-DP
Tal-D
DPd
Event
=276)
N=274)
(N=283)
Any Grade
Grade 3 or 4
Any Grade
Grade 3 or 4
Any Grade
Grade 3 or 4
number of patients (percent)
Any adverse event
276 (100.0)
267 (96.7)
274 (100.0)
216 (78.8)
283 (100.0)
271 (95.8)
Hematologic
Neutropenia
232 (84.1)
211 (76.4)
112 (40.9)
80 (29.2)
255 (90.1)
244 (86.2)
Anemia
136 (49.3)
66 (23.9)
107 (39.1)
41 (15.0)
117 (41.3)
45 (15.9)
Thrombocytopenia
136 (49.3)
66 (23.9)
93 (33.9)
36 (13.1)
108 (38.2)
39 (13.8)
Lymphopenia
99 (35.9)
86 (31.2)
82 (29.9)
68 (24.8)
72 (25.4)
50 (17.7)
Leukopenia
94 (34.1)
63 (22.8)
53 (19.3)
26 (9.5)
79 (27.9)
60 (21.2)
Nonhematologic
Infection
241 (87.3)
104 (37.7)
231 (84.3)
80 (29.2)
235 (83.0)
120 (42.4)
Taste change+
201 (72.8)
—
205 (74.8)
—
11 (3.9)
-
Nonrash skin adverse event
191 (69.2)
6 (2.2)
177 (64.6)
7 (2.6)
24 (8.5)
0
Cytokine release syndrome
187 (67.8)
2 (0.7)
160 (58.4)
2 (0.7)
-
-
Nail-related adverse eventS
155 (56.2)
1 (0.4)
157 (57.3)
1 (0.4)
1 (0.4)
0
Pyrexia
127 (46.0)
8 (2.9)
112 (40.9)
3 (1.1)
35 (12.4)
2 (0.7)
Decreased weight
126 (45.7)
21 (7.6)
105 (38.3)
13 (4.7)
21 (7.4)
1 (0.4)
Rash-related adverse event
105 (38.0)
5 (1.8)
107 (39.1)
7 (2.6)
43 (15.2)
1 (0.4)
Diarrhea
104 (37.7)
7 (2.5)
81 (29.6)
2 (0.7)
79 (27.9)
13 (4.6)
Fatigue
83 (30.1)
14 (5.1)
60 (21.9)
8 (2.9)
69 (24.4)
9 (3.2)
Nausea
79 (28.6)
1 (0.4)
50 (18.2)
1 (0.4)
34 (12.0)
1 (0.4)
Dry mouth
77 (27.9)
1 (0.4)
73 (26.6)
0
3 (1.1)
0
Cough
74 (26.8)
2 (0.7)
70 (25.5)
0
50 (17.7)
1 (0.4)
Hypokalemia
68 (24.6)
17 (6.2)
55 (20.1)
10 (3.6)
45 (15.9)
9 (3.2)
* Shown are adverse events of any grade that occurred in at least 20% of the patients in any trial group. Adverse events were graded with the
Common Terminology Criteria for Adverse Events, version 5.0. The safety population included all the patients who had received at least one
dose of the trial treatment. Safety analyses were conducted according to the treatment received.
f Taste changes included dysgeusia, ageusia, hypogeusia, and taste disorder. According to the Common Terminology Criteria for Adverse
Events, the maximum severity for dysgeusia is grade 2.
$ Nonrash skin adverse events included skin exfoliation, dry skin, pruritus, and palmar-plantar erythrodysesthesia syndrome.
I Nail-related adverse events included nail discoloration, nail disorder, onycholysis, onychomadesis, onychoclasis, and nail ridging.
Rash-related adverse events included rash, maculopapular rash, erythematous rash, and erythema.

---

[Slide 3]
Table S10. Patients with One or More Treatment-emergent Adverse Events (TEAE) Leading to
Discontinuation of All Study Treatment (Safety Population)*
Tal-DP
Tal-D
DPd
(N=276)
(N=274)
(N=283)
Total number of patients with TEAE leading to
29 (10.5)
22(8.0)
19(6.7)
discontinuation of all study treatment, n (%)f
Dysgeusia
5(1.8)
0
0
Ataxia
2 (0.7)
0
0
Cerebellar syndrome
2 (0.7)
0
0
Peripheral sensorimotor neuropathy
2 (0.7)
0
0
Altered state of consciousness
I (0.4)
0
0
Balance disorder
I (0.4)
0
0
Cerebellar ataxia
I (0.4)
0
0
Dysarthria
1 (0.4)
0
0
Neuralgia
I (0.4)
0
0
Slow speech
1 (0.4)
0
0
Cerebral hemorrhage
0
I (0.4)
0
Dizziness
0
I (0.4)
0
Immune effector cell-associated neurotoxicity syndrome
0
I (0.4)
0
Cerebral infarction
0
0
1 (0.4)
Pneumonia
2 (0.7)
3(1.1)
2(0.7)
COVID-19 pneumonia
I (0.4)
0
I (0.4)
Septic shock
I (0.4)
0
I (0.4)
Abdominal infection
I (0.4)
0
0
Epstein-Barr virus infection
I (0.4)
0
0
Urinary tract infection
I (0.4)
0
0
Bronchopulmonary aspergillosis
0
I (0.4)
0
Meningitis cryptococeal
0
1 (0.4)
0
Pneumonia bacterial
0
I (0.4)
0
Pneumonia influenzal
0
1 (0.4)
0
Fungal sepsis
0
0
I (0.4)
Neurocryptococcosis
0
0
I (0.4)
Pneumonia viral
0
0
1 (0.4)
Sepsis
0
0
I (0.4)
Gastric cancer
1 (0.4)
0
1 (0.4)
Acute myeloid leukemia
I (0.4)
0
0
Adenocarcinoma of colon
I (0.4)
0
0
B-cell lymphoma
I (0.4)
0
0
Colon cancer
I (0.4)
0
0
Breast cancer recurrent
0
0
I (0.4)
Castleman's disease
0
0
I (0.4)
Laryngeal squamous cell carcinoma
0
0
1 (0.4)
Fatigue
2(0.7)
I (0.4)
0
Sudden death
I (0.4)
0
2 (0.7)
Gait disturbance
I (0.4)
0
0
Death
0
2 (0.7)
0
General physicalhealth deterioration
0
I (0.4)
0
Malaise
0
I (0.4)
0
Condition aggravated
0
0
I (0.4)
Neutropenia
3(1.1)
I (0.4)
2 (0.7)
Thrombocytopenia
0
2 (0.7)
1 (0.4)
Leukopenia
0
0
2 (0.7)
Lymphopenia
0
0
1 (0.4)
30
Palmar-plantar erythrodysesthesia syndrome
2 (0.7)
I (0.4)
0
Pain of skin
I (0.4)
0
0
Pruritus
I (0.4)
0
0
Pruritus allergic
I (0.4)
0
0
Rash maculo-papular
0
I (0.4)
0
Dry mouth
2 (0.7)
I (0.4)
0
Dysphagia
0
I (0.4)
0
Glossitis
0
I (0.4)
0
Upper gastrointestinal hemorrhage
0
0
1 (0.4)
Oropharyngeal pain
2(0.7)
I (0.4)
0
Respiratory failure
0
1 (0.4)
I (0.4)
Chronic respiratory failure
0
0
I (0.4)
Muscular weakness
I (0.4)
0
0
Arthralgia
0
I (0.4)
0
Flank pain
0
0
1 (0.4)
Vertigo
I (0.4)
0
0
Peripheral nerve injury
I (0.4)
0
0
Weight decreased
1 (0.4)
0
0
Hypotension
1 (0.4)
0
0
Cytokine release syndrome
0
2(0.7)
0
Decreased appetite
0
I (0.4)
I (0.4)
Cardiac arrest
0
0
I (0.4)
Cardiac failure
0
0
1 (0.4)
Myocardial rupture
0
0
I (0.4)
Acute kidney injury
0
0
2 (0.7)
Renal impairment
0
0
(0.4)
. The safety population was defined as all randomized patients who received at least one dose of study treatment
Adverse events are coded using MedDRA Version 28.0. Adverse events are graded according to the NCI-CTCAE Version
5.0. except for ICANS and CRS. which were graded by ASTCT consensus grading system.

Ankit kansagra@kansagraMD

EHA 2026 · 2026-05-12

5.7K impressions · 42 likes

[Slide 1]
Summary/Conclusion:
Tal-DP and Tal-D demonstrated a significant and profound PFS benefit VS DPd, clinically meaningful OS improvements and gr >3 infection rates similar to or lower than
DPd. Tal was combinable, with low rates of tx d/c. Efficacy appeared numerically better with Tal-DP VS Tal-D but with a higher gr 3-4 cytopenia rate, as expected with
Pom. Tal-D with or without Pom represents a new standard of care for RRMM as early as 2L across all practice settings.
A
B
+ Tal-DP + DPd
Tal-DP
100
Tal 0.8 mg/kg SC Q2W from
C1 through C4-6 then Q4W"
24-mo PFS (95% CI)
81.3% (75.8-85.7)
Dara 1800 mg SC QW for
C1-2, Q2W C3-6, then Q4W
80
Pom 2 mg daily for 21 days
per C from C2b
% of patients progression-free and alive
60
24-mo PFS (95% CI)
51.2% (44.8-57.1)
Tal-D
Tal 0.8 mg/kg SC Q2W from
40
C1 through C4-6 then Q4W
Dara 1800 mg SC QW for
C1-2, Q2W C3-6, then Q4W
20
Tal-DP
DPd
N=287
N=290
Median PFS (95% CI), mo
NR (NE-NE)
24.4
(19.3-NE)
DPd
HR (95% CI)
0.28 (0.20-0.40)
P<0.0001
Dara 1800 mg SC QW for
0
C1-2, Q2W C3-6, then Q4W
0
3
6
9
12
15
18
21
24
27
30
33
36
Pom 4 mg daily for 21 days
Months
per C from C1
Number at Risk
Dex 40 mg (age <75) or 20 mg
Tal-DP
287
266
255
240
229
218
212
169
116
74
32
8
0
(BMI <18.5 or age >75) QW
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0
C
Tal-D
DPd
100
24-mo PFS (95% CI)
80
77.6% (71.7-82.5)
Clinical cut-off: November 2025.
Median follow-up was 24.6 mo
(range 0.03-35.4). For panels B and
C, PFS was estimated using the
% of patients progression-free and alive
60
24-mo PFS (95% CI)
Kaplan-Meier method; treatment
51.2% (44.8-57.1)
comparisons were made using a
stratified log-rank test. HRs and
95% Cls were calculated using a Cox
40
proportional hazards model. Disease
evaluations were by independent
review committee per IMWG
criteria. BMI, body mass index; C,
cycle; Dex, dexamethasone; SC,
20
Tal-D
DPd
subcutaneous; QW, weekly; Q2W,
N=287
N=290
every other week; Q4W every 4
Median PFS (95% CI), mo
NR (NE-NE)
24.4 (19.3-NE)
weeks.
HR (95% CI)
0.33 (0.24-0.46)
P<0.0001
"Tal could be reduced to Q4W at
0
C5-6 with a very good partial
response or better or at C7 with a
0
3
6
9
12
15
18
21
24
27
30
33
36
partial response or better. Pom
Months
Number at Risk
could be increased to 4 mg at C3D1
if indicated.
Tal-D
287
262
256
238
225
216
207
159
98
62
30
8
0
DPd
290
249
223
198
175
158
146
113
81
44
22
2
0

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

2.3K impressions · 5 likes

[Slide 1]
Table S19. Treatment-emergent Ataxia/balance disorders (Safety Population)*
Tal-DP
Tal-D
DPd
Parameter
(N=276)
(N=274)
(N=283)
Ataxia and balance disorders +
40 (14.5)
34 (12.4)
1 (0.4)
Ataxia
15 (5.4)
14 (5.1)
0
Dysarthria
12 (4.3)
11 (4.0)
0
Balance disorder
8 (2.9)
7 (2.6)
0
Nystagmus
8 (2.9)
1 (0.4)
0
Cerebellar ataxia
4 (1.4)
1 (0.4)
0
Cerebellar syndrome
3 (1.1)
1 (0.4)
0
Dysmetria
1 (0.4)
0
0
Gait disturbance
8 (2.9)
10 (3.6)
1 (0.4)
Grade 3, n (%) :
8 (2.9)
6 (2.2)
0
Leading to talquetamab dose delays or skips, n (%)
21 (7.6)
23 (8.4)
-
Leading to discontinuation of talquetamab, n (%)§
13 (4.7)
6 (2.2)
-
Leading to discontinuation of all study treatment, n (%)
7 (2.5)
0
0
Time to onset from first dose of study treatment, median
292 (3-1034)
326 (24-873)
21 (21-21)
(range), days
Duration, median (range), days
106.5
108.0
-
(10-808)
(1-385)
Outcome, n (%) #
Number of events
93
65
1
Recovered or resolved
10 (10.8)
11 (16.9)
0
Not recovered or resolved
82 (88.2)
44 (67.7)
0
Recovered or resolved with sequelae I
0
1 (1.5)
0
Recovering or resolving
1 (1.1)
5 (7.7)
0
Missing
0
4 (6.2)
1 (100)
*The safety population was defined as all randomized patients who received at least one dose of study treatment.
+ Including ataxia, dysarthria, balance disorder, nystagmus, cerebellar ataxia, cerebellar syndrome, dysmetria, and gait
disturbance.
: There were no grade >4 events.
$ Events with action taken to talquetamab as drug withdrawn on the adverse event electronic clinical report form page.
1 Includes those patients indicated as having discontinued all study treatment due to adverse events on the end-of-treatment
clinical report form page.
# Total number of events for the given treatment arm is used as the denominator.
I Indicates that the adverse event was recorded as resolved at the time of reporting, but the patient subsequently had
persistent, recurrent, or later-emerging neurologic findings within the overall clinical course. This does not imply
continuous unresolved symptoms from the index event.

Samer Al Hadidi, MD,MS,FACP@hadidisamer

EHA 2026 · 2026-06-13

1.1K impressions · 18 likes

Vincent Rajkumar@vincentrk

EHA 2026 · 2026-06-13

917 impressions · 17 likes

Ankit kansagra@kansagraMD

Most Discussed

MonumenTAL-3 Top Tweets

Bispecific in 2L myeloma — New Combinations enters the race @PlasmaCellPete @mbeksac56 @RahulBanerjeeMD @paurotero @thanosdimop and amazing team of invetigators/sponsor. MonumenTAL-3, EHA Plenary (Voorhees et al). 1:1:1, n=864: Tal+Dara+Pom (Tal-DP) vs Tal+Dara (Tal-D) vs DPd. https://t.co/sJvKwc4lg0

👁 5.7K❤ 42🔁 132026-05-12

#mmsm #EHA26 MonumenTAL-3 Published @NEJM 🛑Ataxia/balance disorders: Tal-DP 15%, Tal-D 12%, DPd 0.4%. 🛑Onset is late: median ~292–326 days, increasing from cycle 7 onward (11% Tal-DP, 10% Tal-D)-Led to talquetamab discontinuation: 5% (Tal-DP) vs 2% (Tal-D) The major issue https://t.co/U9WE9EXgcZ

👁 2.3K❤ 5🔁 02026-06-13

#mmsm #EHA26 MonumenTAL-3 Published @NEJM ➡️ https://t.co/tRTOmHky2O ✅RCT, phase 3: Tal-DP vs Tal-D vs DPd ✅ Treatment was until progression or intolerance (not time-limited) ✅ Early relapse ≥1 prior line including lenalidomide + PI ( no anti-CD38 refractory) ✅allowed https://t.co/R8IeEr5FpI

👁 1.1K❤ 18🔁 82026-06-13

Vincent Rajkumar@vincentrk

Just out: presented at #EHA26 and published @NEJM Randomized trial of 2 talquetamab combinations vs DPd in relapsed myeloma. The Monumental-3 trial. Both Talq-Dara-Pom and Talq-Dara beat DPd in PFS and OS. Choice of a Talq combination vs Tec or Tec-Dara in relapsed myeloma https://t.co/mgSlY8T8cu

👁 917❤ 17🔁 92026-06-13

Rahul Banerjee, MD, FACP@rahulbanerjeemd

@Dr_AmerZeidan @EHA_Hematology In myeloma - @PlasmaCellPete will be presenting MonumenTAL-3 Ph3 RCT of talquetamab +/- Dara/pom in earlier lines #MMsm. We have gotten a bit too hooked on BCMA as a field… So a BCMA-sparing PI-sparing dex-sparing bsAb regimen in earlier lines is a big #EHA2026 plenary win!

👁 810❤ 23🔁 42026-06-11

#mmsm #EHA26 MonumenTAL-3 Published @NEJM ✅ median FU ~ 2 yrs ✅n=864 ✅median age: 64 (range:30-88 yrs) ✅median 2 prior lines (range 1–8) , ~1/3 had only 1 prior line ✅~12% prior daratumumab ✅ ~69% prior SCT https://t.co/VqlrpVM0XU

👁 645❤ 3🔁 12026-06-13

Rahul Banerjee, MD, FACP@rahulbanerjeemd

#EHA2026 a new standard of care about to emerge in myeloma! @PlasmaCellPete looking as presidential as ever at the plenary session 💪 MonumenTAL-3: tal-dara +/- pom versus Dara-Pd. Tal-DP and tal-D both dramatically outperformed D-Pd! https://t.co/tp9t1XQyKK

👁 426❤ 17🔁 72026-06-13

Daniel Auclair@auclairdan

MonumenTAL-3 study is out published simultaneously with presentation here at #EHA26 #EHA2026 by @PlasmaCellPete Congrats! #mmsm https://t.co/it0zv1Jr15

👁 418❤ 6🔁 72026-06-13

#mmsm #EHA26 MonumenTAL-3 Published @NEJM ✅ median treatment duration: ~22 months (Tal-DP), ~22 months (Tal-D), ~19 months (DPd) ✅treatment discontinued: Tal-DP 30%, Tal-D 30% | DPd 53%, mainly progressive disease (13% vs 16% vs 40%) and adverse events (13% vs 8% vs 7%) https://t.co/ZD2lH3P9ZG

👁 416❤ 5🔁 02026-06-13